Secondary Logo

Journal Logo

Original Studies

Treatment for vaginal atrophy using microablative fractional CO2 laser: a randomized double-blinded sham-controlled trial

Ruanphoo, Purim MD; Bunyavejchevin, Suvit MD, MHS

Author Information
doi: 10.1097/GME.0000000000001542


Vulvovaginal atrophy or atrophic vaginitis refers to a group of postmenopausal symptoms related to an alteration of the vulva, vagina, and lower urinary tract. The International Society for the Study of Women's Sexual Health and The North American Menopause Society proposed the nomenclature, “genitourinary syndrome of menopause” as a new terminology. These symptoms are associated with the decrement of estrogen after menopause.1 The low levels of circulating estrogen produce a wide variety of anatomic, physiologic, and clinical changes in the urogenital area.2 Clinical symptoms include vaginal dryness, irritation, soreness, dyspareunia, dysuria, and vaginal discharge. On examination, thinning, dryness, and pallor of the vaginal mucosa and flatten labia majora owing to loss of labial fat pad are common findings. As atrophy progresses, petechial hemorrhage may be found in the mucosa causing the vagina to become short and narrow.1-3 Almost half of the postmenopausal women were reported to have vaginal atrophy.1,4,5 This percentage may, however, actually be underestimated due to underreporting by the patients or underrecognized by the healthcare providers. Evidence suggested that vaginal atrophy has profound negative effects on sexual health and quality of life.4,5 Hence, it is important to treat postmenopausal women with vaginal atrophy.

The treatment regimens, according to the 2013 position statement of The North American Menopause Society on management of symptomatic vulvovaginal atrophy, are nonprescription therapies; lubricants, moisturizers, herbal dietary supplements (eg, black cohosh, soy, or other herbs), and prescription therapies; vaginal estrogen, which is the criterion standard for treating vaginal atrophy.5 Selecting the treatment for vaginal atrophy depends on several factors such as severity of the condition, patient preference, effectiveness, and safety of the treatment. Ospemifene, which is a Selective Estrogen Receptor Modulator, is the other treatment option for moderate to severe dyspareunia associated with vaginal atrophy.5-9 In recent years, microablative fractional CO2 laser has become available for treating pelvic floor dysfunction including vaginal atrophy. It showed a regenerative property with significant histological changes in cellular and connective tissue components.10,11 Several prospective studies reported significant improvement of signs and symptoms of vaginal atrophy including health-related quality of life after being treated with vaginal CO2 laser. There were three case series that reported on the long-term positive effect of vaginal laser on vaginal atrophy symptoms (VAS; burning, dryness, and dyspareunia), Vaginal Health Index (VHI), and Female Sexual Function Index score for at least 1 year after three sessions of fractional CO2 laser.12-14 Up to now, there are only a few studies reporting on the efficacy and safety of microablative fractional CO2 laser by comparing it to the criterion standard therapy such as vaginal estrogen.15 But there is no report comparing vaginal laser with placebo or sham procedure. As a result, we conducted a randomized controlled trial to evaluate the efficacy of microablative fractional CO2 laser by comparing it to a placebo (sham) procedure for the treatment of vaginal atrophy in postmenopausal women.


From June 2016 to May 2017, a prospective randomized controlled trial was conducted at the Gynecology Clinic, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. This study was approved by the Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University on March 31, 2016 (COA No. 276/2016). The study was registered in the Thai Clinical Trial Registry (No. TCTR20160627002).


Postmenopausal women (aged at least 50 years and had their last menstruation at least 1 year ago) with any VAS (moderate to severe intensity) were invited to participate in the study. Details of the study protocol, nature of the randomized trial, benefit, and risk of participating in the study were provided to the participants before enrollment. Written informed consent was obtained from all participants before enrollment. Women who had any history of hormonal therapy within the past 6 months, vaginal moisturizer or lubricant applications within the past 30 days, acute/recurrent urinary tract infection, or active genital infection were excluded from the study. In addition, if the participant was found to have a genital hiatus diameter of less than 2 cm (smaller than the vaginal probe size) or have pelvic organ prolapse stage 2 or higher according to pelvic organ prolapse quantification system classification,16 they were also excluded.

Study protocol

Participants were randomized to either the laser group or the sham group (1:1 ratio). Simple randomization was generated by the computer. Allocation concealment of the generated codes was kept in opaque, sealed envelopes. The envelopes were opened by a research assistant at the first visit before initiating treatment. Demographic data and detailed medical history of all participants were collected including age, age at menopause, parity, type of delivery, history of vaginal reconstructive surgery, history of hormonal treatment, and sexual activity status. All participants were scheduled for four visits (V1, V2, V3, and V4) with a 4-week interval.

At each visit (V1, V2, V3, and V4), the participants were interviewed to assess the intensity of VAS using the VAS score.17 Signs of vaginal atrophy were evaluated during pelvic examination using a validated tool—VHI score18 by an investigator (S.B.) who was blinded to the participant's treatment. All participants were asked to answer item number 7 of the Thai-version International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms (ICIQ-VS) questionnaire19 to assess vaginal atrophy. After pelvic examination and completion of the questionnaire, the interventions were performed. The participants received the interventions in the first three visits (V1, V2, and V3). Laser or sham treatment was performed by an investigator (P.R.) who did not know the clinical outcomes of the treatment. In the last visit (V4), the study assessed the participants’ satisfaction with the treatment and any adverse events they experienced during the study period.

Vaginal microablative fractional CO2 laser treatment

The participants in the laser treatment group received the intervention by using the CO2 laser machine (SmartXide2 V2LR, DEKA, Florence, Italy). The laser settings were DEKA pulse mode, dot power 40 W, dwell time 1,000 ms, dot spacing 1,000 μm, and the smart stack parameter from 1 to 3. In the lithotomy position, the vaginal laser probe was inserted into the total length of the vagina and subsequently withdrawn 0.5 cm following each laser beam application until the distal end of the vaginal probe reached the introitus. The laser application was performed on an outpatient basis without local anesthesia. Participants were advised to avoid sexual intercourse or intravaginal devices for at least 3 days after the procedure owing to transient local inflammation at the vaginal mucosa generated by the laser application.

Sham procedure

Sham procedure was defined as a procedure mimicking the laser procedure without using the laser. Vaginal probe was inserted and withdrawn in the same manner as the laser treatment while the participants were in lithotomy position. Postprocedural recommendation was similar to the women who received the laser treatment.

Outcome measurements

The primary outcome was VHI score. The secondary outcomes were VAS score, score for the item for vaginal dryness (from ICIQ-VS questionnaire), participant's satisfaction with the procedures, and adverse events after the interventions. The outcome measurements were defined as follows.

Vaginal atrophy symptoms score

VAS score in this study was modified from Davila et al's study.17 We assessed four domains of VAS: dryness, irritation, soreness, and dyspareunia. The intensity of each domain was graded as none (0), mild (1), moderate (2), or severe (3). The total VAS score was calculated by the sum of these individual symptom scores divided by 4 for sexually active participants. For those participants who were not sexually active, the sum of individual symptom scores were divided by 3. Higher scores represent more severity of VAS.

Vaginal health index score

VHI score determines the severity of five signs of vaginal atrophy: elasticity, fluid volume, pH, epithelial integrity, and moisture. Each sign is rated from one to five. Summation of these scores represents the total VHI score which ranges from 5 to 25. High scores indicated less severity of vaginal atrophy.18

Vaginal dryness score of International Consultation on Incontinence Modular Questionnaire-Vaginal Symptoms questionnaire

ICIQ-VS questionnaire is a self-completed tool to assess the severity and impact of vaginal symptoms including vaginal atrophy. It has been translated and validated in the Thai language. The questionnaire consists of 14 items divided into 3 domains: vaginal symptoms, sexual matter, and quality of life. We chose item number 7 which provides information regarding vaginal dryness to assess for the symptom of vaginal atrophy.19

Adverse events

At the last visit (V4), all participants were asked about any adverse events after the interventions (eg, vaginal bleeding, discharge, vaginitis, pain after the procedure was done, and de novo dyspareunia).

Participant's satisfaction

At the last visit (V4), the participants were asked to answer a self-completed satisfaction questionnaire. The questionnaire used a five-point Likert scale (ie, very dissatisfied, dissatisfied, neutral, satisfied, and very satisfied) to assess the participant's satisfaction with the intervention.

Sample size calculation

The sample size calculation was based on the primary efficacy variable (VHI score), a 5% level of significance (two-sided), and a power of 80% were assumed. Previously, we conducted a pilot study so that the results obtained from that study were used to calculate the sample size for this trial. Data from our pilot study showed mean ± SD of VHI after 12 weeks of laser treatment was 20.5 ± 4.5 and mean ± SD of VHI after 12 weeks of no laser treatment was 18 ± 2.8. With 1:1 ratio, a sample size of 44 women per group was required taking into account a 20% dropout rate.

Statistical analysis

For baseline characteristics, categorical data were presented as number and percentage. Continuous data were presented as mean and standard deviation or median and interquartile range as appropriate. Intention-to-treat (ITT) analysis was used for primary outcome. When comparing the outcomes between pretreatment and posttreatment, paired t test or Wilcoxson sign rank test was used for continuous data. To compare outcomes between groups, continuous data were analyzed using unpaired t test or Mann-Whitney U test and categorical data were analyzed using chi-square test.

When there were missing data for any baseline characteristic variables, those participants would be excluded from the analysis. When outcome variables were missing, multiple imputation was used by regressing the outcomes on the other observed data using a linear regression model because we assessed the outcomes at multiple time points. All data were analyzed using SPSS software version 22.0 (SPSS science, Chicago, IL) for Windows. P value less than 0.05 was considered statistically significant.

Our statistical analysis plan did not include a plan for managing confounding variables on the primary outcome. Data from baseline characteristics demonstrated that sexually active lifestyle was different between the two groups. There is evidence that sexual function may relate to vaginal atrophy,20-22 so we performed analysis of covariance to control the confounding effect of the sexually active variable.


A total of 88 participants were randomized. In the laser group (n = 44), three participants withdrew from the study. One participant withdrew from the study because she could not tolerate the pain when the vaginal probe was inserted into the vagina. The other two women withdrew from the study claiming that it was inconvenient for them to come according to the schedule of the study. In the sham group (n = 44), six participants were lost to follow-up because it was inconvenient for them to come in to receive the treatment. Because we planned to use the ITT analysis for this study, all 44 participants from each group were included for analysis (Fig. 1). Linear regression technique was used to impute those missing outcome data for the analysis. We had nine missing outcome data (three in the laser group and six in the sham group). The mean ± SD age of the enrolled women was 60.78 ± 7.77 years. The mean ± SD age at menopause was 49.21 ± 3.49 years. Thirty-four women (38.64%) were sexually active (10 [22.73%] in the laser group and 24 [54.55%] in the sham group; Table 1).

FIG. 1
FIG. 1:
CONSORT flowchart of participants.
Demographic data

Outcome measurements at baseline are shown in Table 2. In the laser group, the mean ± SD VHI and VAS scores were 14.18 ± 3.39 and 2.27 ± 0.42, respectively. In the sham group, the mean ± SD VHI and VAS scores were 14.66 ± 2.91 and 2.02 ± 0.40, respectively. At baseline, the VHI score (P = 0.48), VAS score (P = 0.06), and ICIQ-VS, the item for vaginal dryness (P = 0.09) were comparable between both groups (Table 2). Data were compared between baseline and 12-week follow-up (Table 2). In the laser group, there was significant improvement for all outcomes at week 12 when compared to baseline. The VHI score significantly increased from 14.18 ± 3.39 at baseline to 17.45 ± 2.61 at 12-week follow-up, P < 0.001. The VAS score decreased from 2.27 ± 0.42 to 1.83 ± 0.51, P < 0.001. As for ICIQ-VS, the item for vaginal dryness significantly decreased from 5.00 (2.00-6.00) to 3.24 (0-4.00), P = 0.02. In the sham group, there was no statistical difference of the VHI score at 12-week follow-up period (P = 0.06). The VAS score increased from 2.02 ± 0.40 at baseline to 2.06 ± 0.49 at 12-week follow-up (P = 0.59). The ICIQ-VS, the item for vaginal dryness decreased at week 12 (P = 0.07) (Table 2).

Vaginal signs and symptoms at baseline and 12 weeks after treatment

Because the outcomes at baseline were not significantly different between groups, we assumed that the outcomes at 12-week follow-up could represent the change after treatment. When we compared the outcomes at 12-week follow-up with the ITT analysis, there was statistically significant differences between the two groups for VHI score (P < 0.001) and VAS score (P = 0.03) with the mean difference of 1.37 (95% CI: 0.12-2.63) and −0.23 (95% CI: −0.45 to −0.27), respectively. There was, however, no significant differences for ICIQ-VS, the item for vaginal dryness (P = 0.56) (Table 2). The results from per-protocol analysis were similar to the ITT analysis. A one-way analysis of covariance was conducted to determine whether there were any significant differences between the laser and sham groups for VHI score at 12-week follow-up after controlling for active sexual status. After the active sexual status was controlled, we saw a significant improvement in the VHI score in the laser group compared to the sham group (F (1,86) = 6.47, P < 0.05).

Seventy-seven women answered the satisfaction evaluation questionnaire (39 women from the laser group and 38 women from the sham group). The comparison of the participants’ satisfaction from both groups is shown in Table 3. There was a significant difference between the two groups for “very satisfied or satisfied” and “neither satisfied nor dissatisfied or lower” (P = 0.002). Participants experiencing minor adverse events (ie, vaginal bleeding, vaginal discharge, vaginitis, and pain after procedure) are shown in Table 4. The adverse events were not statistically significant between the groups. One participant from the laser group was diagnosed with bacterial vaginosis 1 week after the procedure and was treated with oral metronidazole for 7 days.

Comparison of the participants’ satisfaction between the laser and sham groups
Comparison of the complications between the laser and the sham groups


Vaginal microablative fractional CO2 laser for treatment of vaginal atrophy is the activation of vaginal tissue to regenerate. The supraphysiologic level of the heat from the laser induces production of a variety of growth factors, which induce cell proliferation and subsequent tissue repair.23 Microscopic evaluation of the vaginal tissue after laser treatment showed thickening of the epithelial layer and increase papillae projecting from the connective tissue into the epithelium, which represent the regenerative characteristic of the vaginal mucosa that is similar to the premenopausal vaginal mucosa.10,11

Our randomized trial showed that after 12 weeks of treatment with vaginal CO2 laser, there were significant improvements in the VHI score and VAS score among women with vaginal atrophy, whereas in the sham group, there were no significant improvements for all measurements. These results were consistent with other previous uncontrolled prospective studies that showed vaginal CO2 laser treatment did improve symptoms and signs of vaginal atrophy.12-14,24-26 In a previous randomized-controlled trial conducted by Cruz et al,15 they evaluated the efficacy of fractional CO2 laser and compared it to local estrogen and the combination of both treatments. Participants were randomly assigned to three treatment arms: laser with estriol treatment, laser with placebo treatment, and sham procedure with estriol treatment. After 20 weeks, the participants who received laser with estriol treatment and laser with placebo treatment showed significant improvement in VHI and VAS compared to the participants that were only treated with estriol. In another randomized trial, the effects of fractional CO2 laser therapy were compared to vaginal promestriene and vaginal lubricants among women with genitourinary syndrome of menopause.27 The women from the CO2 laser group had a significantly higher VHI score after 14 weeks of treatment compared to women in the promestriene and lubricant groups. Vaginal maturation significantly improved in the CO2 laser group compared to the other treatment groups, but it should be noted that they did not compare the results of the laser group to a sham group to confirm the efficacy of CO2 laser versus placebo. Our study is the first trial that compared the effect of vaginal CO2 laser with the placebo (sham procedure) to see whether the placebo effect can improve VAS. Our results confirmed that the CO2 laser could improve VHI and VAS when compared to the sham group. After completion of the study, all participants were treated according to The North American Menopause Society guideline for vaginal atrophy among postmenopausal women.5 We detected minor adverse effects of the vaginal laser which were similar to previous reports.12,14,15,27 These side effects lasted only for a few days. No serious adverse event was noted in this study.

The strength of this study was its randomized trial design that compared the effects of vaginal CO2 laser to the sham procedure. Also, the dropout rate in the study was small. In addition, this study was double blinded so bias was minimized. Moreover, we used the standardized outcome measurements (VHI and VAS scores) and validated questionnaire (ICIQ-VS, item for vaginal dryness) to assess vaginal atrophy. Furthermore, the vaginal laser and the sham procedures were performed by a single operator to avoid interpersonal clinical skill variation.

This study had some limitations. First, we did not study the effect of vaginal laser on sexual function28 because sexual activity among Thai menopausal women was low (38%). Second, the follow-up period in this study was only 12 weeks. Thus, additional study with a longer follow-up period and larger sample size should be conducted to assess the long-term effects of vaginal CO2 laser in terms of efficacy and side effects. Third, the sham procedure was performed in the same manner as the laser treatment but without laser power application. Participants might, however, perceive that there was no noise and vibration during the procedure. This might cause unblinding to those participants and result in bias to participants’ reported outcomes. Fourth, we assessed adverse events at the last visit. This could be a source of recall bias because participants might not recall the discomfort which occurred in the previous visits.


Vaginal microablative fractional CO2 laser was effective in treating women with vaginal atrophy compared to the sham procedure at week 12. Vaginal microablative fractional CO2 laser could be an alternative treatment for postmenopausal women with vaginal atrophy.


1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85:87–94.
2. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Maturitas 2014; 79:349–354.
3. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17:3–9.
4. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6:2133–2142.
5. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20:888–902.
6. Hutchinson-Colas J, Segal S. Genitourinary syndrome of menopause and the use of laser therapy. Maturitas 2015; 82:342–345.
7. Rees M, Perez-Lopez FR, Ceasu I, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012; 73:171–174.
8. Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015; 82:308–313.
9. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10:1790–1799.
10. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 2015; 30:429–436.
11. Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015; 22:845–849.
12. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014; 17:363–369.
13. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric 2015; 18:219–225.
14. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015; 80:296–301.
15. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018; 25:21–28.
16. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996; 175:10–17.
17. Davila GW, Singh A, Karapanagiotou I, et al. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 2003; 118:382–388.
18. Bachmann GA, Notelovitz M, Kelly SJ, Thompson C. Long-term nonhormonal treatment of vaginal dryness. Clin Pract Sex 1992; 8:12–17.
19. Sriwat W, Manonai J, Sillaphakit C, Sarit-apirak S, Chittacharoen A. Validation of the Thai Version of ICIQ-VS (International Consultation on Incontinence Questionnaire -Vaginal symptoms) in Thai Women. Ramathibodi Med J 2016; 39:1–13.
20. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005; 2: (suppl 3): 154–165.
21. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004; 1:82–86.
22. Basson R, Brotto LA, Laan E, Redmond C, Utian WH. Assessment and management of women's sexual dysfunctions: problematic desire and arousal. J Sex Med 2005; 2:291–300.
23. Prignano F, Campolmi P, Bonan P, et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther 2009; 22: (suppl 1): S8–S15.
24. Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016; 23:1102–1107.
25. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 2016; 294:841–846.
26. Pitsouni E, Grigoriadis T, Tsiveleka A, Zacharakis D, Salvatore S, Athanasiou S. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas 2016; 94:131–136.
27. Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause 2019; 26:833–840.
28. Knodel J, Chayovan N. Sexual activity among older Thais: the influence of age, gender and health. J Cross Cult Gerontol 2001; 16:173–200.

Fractional carbon dioxide laser; Genitourinary syndrome of menopause; Vaginal atrophy; Vaginal laser

Supplemental Digital Content

© 2020 by The North American Menopause Society